Skip to main
NBTX

Nanobiotix SA (NBTX) Stock Forecast & Price Target

Nanobiotix SA (NBTX) Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 33%
Buy 33%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

Nanobiotix is shaping up to be a strong player in the biotechnology landscape, with a promising lead program in NBTXR3, a unique physics-based approach to treating cancer that has shown positive results in clinical studies. The company also has a lucrative collaboration with JNJ for the development and commercialization of NBTXR3, providing a potential stream of royalties and milestones. While there are potential clinical and commercial risks, the data and collaboration support a positive outlook for Nanobiotix's stock.

Bears say

Nanobiotix is currently in a strong financial position with a cash runway lasting until 2029, but faces significant risks due to the early stage of its pipeline and the highly novel nature of its lead program, NBTXR3. Downside risks include potential clinical trial failures, safety concerns, regulatory setbacks, and challenges with commercial performance post-approval. Additionally, the company's recent focus on its Curadigm platform could also pose challenges with commercialization.

Nanobiotix SA (NBTX) has been analyzed by 3 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 33% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Nanobiotix SA and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Nanobiotix SA (NBTX) Forecast

Analysts have given Nanobiotix SA (NBTX) a Buy based on their latest research and market trends.

According to 3 analysts, Nanobiotix SA (NBTX) has a Buy consensus rating as of Aug 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $37.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $37.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Nanobiotix SA (NBTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.